StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Stock analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.19 on Friday. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.68. The business has a fifty day moving average price of $0.31 and a 200 day moving average price of $0.49. The stock has a market capitalization of $11.39 million, a P/E ratio of -0.06 and a beta of 1.06.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.